Roche has secured CE mark approval for its immunohistochemistry (IHC) companion diagnostic test, VENTANA FOLR1 (FOLR1-2.1) ...

Swiss drug major Roche Group (RHHBY) announced Monday that it has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, ...

The immunohistochemistry test detects the folate receptor 1 protein, which is over-expressed in most ovarian cancers.

On November 8, 2024, Roche Diagnostics enhanced the company's long term commitment to China's local healthcare industry, to ultimately benefit patients in China and beyond, with the opening of its ...

Roche has announced a new 'open innovation' research alliance in nanotechnology to develop new diagnostic tools. The Swiss company is to work with BioMed X, a new open innovation lab in Heidelberg ...

Presented at the Clinical Trials in Alzheimer’s Disease congress, being held in Madrid, Spain, Roche’s diagnostics unit showed that a negative result from one test—its Elecsys amyloid plasma ...

Roche Diagnostics has received a CE mark for Elecsys anti-müllerian hormone (AMH) plus immunoassay as a diagnostic blood test for PCOS. AMH is produced by granulosa cells in ovarian follicles.

The alliance is with Roche Tissue Diagnostics (RTD), a unit of the Swiss pharma group that is concerned with the development of tissue-based tools to improve the diagnosis of cancer and grew out ...

thanks to growth in both its pharmaceuticals and diagnostics businesses. Excluding currency movements, sales grew 9%, with increases in both divisions, Roche said.